

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

CLARIFICATION ANNOUNCEMENT

Reference is made to the Company's announcements dated October 28, 2025 (the "**October 28 Announcement**") and October 29, 2025 (the "**October 29 Announcement**", together with the October 28 Announcement, the "**Previous Announcements**"). This announcement is made by Jenscare Scientific Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") to provide clarification on the Previous Announcements to clarify the revisions which were made in the Previous Announcements correcting an inadvertent error in the October 28 Announcement. Unless otherwise defined, capitalized terms used in this announcement shall have the same meaning as used in the Previous Announcement.

The Company would wish to clarify that the two places related to the follow-up period of the safety results set out on page 2 of the October 28 Announcement were revised in the October 29 Announcement, but all the safety results were presented accurately and remained unchanged, and the changes made between the two announcement are annotated below for ease of reference:

The safety results showed:

Clinical Event Committee (CEC) – adjudicated Composite Events 30-day	(FAS + Roll-in, N=161) At 6 months
Cardiovascular mortality	6 (3.7%)
Myocardial infarction	0 (0.0%)
Strokes	1 (0.6%)
New onset renal failure	2 (1.2%)
Severe bleeding (includes fatal, life-threatening and extensive bleeding as defined by MVARC)	8 (5.0%)
Non-selective tricuspid valve surgery/intervention post procedure	4 (2.5%)
Major cardiac structural complications	5 (3.1%)
Major access site and vascular complications	0 (0.0%)
Device-related pulmonary embolism	0 (0.0%)
New pacemaker implantation due to AV block	14 (8.7%)
New pacemaker implantation due to AV block (Naive)	14 (11.9%)

The overall CEC-adjudicated composite events rate at ~~30-Day~~6 months of FAS + Roll-in group is 19.9%.

Save as indicated in this announcement, all the other information and content contained in the Previous Announcements remain unchanged.

Cautionary Statement as required by Rule 18A.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop and market LuX-Valve Plus and JensClip and/or commercialize Ken-Valve successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jenscare Scientific Co., Ltd.
Mr. PAN Fei

Executive Director and Chief Executive Officer

Hong Kong, October 30, 2025

As at the date of this announcement, the executive Director is Mr. PAN Fei; the non-executive Directors are Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.